Windward Bio Group, a Switzerland-based biotechnology company developing long-acting antibody treatments for respiratory and dermatological diseases, announced terms for its initial public offering on Monday. The company plans to raise $175 million through the sale of approximately 10.3 million shares at a proposed price range of $16 to $18. Separately, it intends to raise an additional $50 million through a private placement to Sanofi. At the midpoint of the proposed IPO range, Windward Bio Group would have a fully diluted market value of approximately $1 billion.
Company Background and Business Overview
Founded in 2024 and headquartered in Basel, Switzerland, Windward Bio Group is developing ultra-long-acting antibodies for asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. Its approach is designed to reduce treatment frequency compared with currently available therapies.
The company’s pipeline includes two principal antibody candidates, WIN378 and WIN027. Its lead candidate, WIN378, targets thymic stromal lymphopoietin (TSLP), the same target as the approved treatment Tezspire. Windward Bio is developing WIN378 for twice-yearly administration, compared with Tezspire’s dosing schedule of once every four weeks.
Clinical Pipeline and Development Progress
WIN378 is being evaluated in a Phase 2/3 trial for severe uncontrolled asthma and a Phase 2 trial for COPD. The company expects primary results from the asthma Phase 2 trial in the first half of 2027.
Its second candidate, WIN027, is a bispecific antibody targeting both TSLP and interleukin-13 (IL-13). The candidate is currently in a Phase 1 trial. Windward Bio plans to begin enrolling patients in Phase 2 trials evaluating WIN027 in COPD and atopic dermatitis during the first half of 2027.
The company’s development strategy centers on antibody treatments intended to provide longer-lasting therapeutic effects, potentially reducing the frequency of administration for patients with chronic inflammatory conditions.
IPO Details and Sanofi Private Placement
Windward Bio Group plans to raise $175 million by offering approximately 10.3 million shares at a price range of $16 to $18. At the midpoint of the proposed range, the company would command a fully diluted market value of approximately $1 billion.
In addition to the public offering, Sanofi has agreed to participate in a concurrent private placement worth $50 million. The investment provides a separate source of capital alongside the proposed IPO.
The company plans to list on the Nasdaq under the symbol WWB. Jefferies, TD Securities, Piper Sandler, and UBS Investment Bank are serving as joint bookrunners. The offering is expected to take place during the week of November 9, 2026.
Market Context and Challenges
Windward Bio is entering the public market with two antibody candidates at different stages of clinical development. WIN378 has advanced into Phase 2 and Phase 2/3 studies, while WIN027 remains in Phase 1 development.
The company’s proposed twice-yearly dosing schedule for WIN378 distinguishes its development approach from the four-week administration schedule cited for Tezspire. However, the candidates remain investigational, and their clinical development programs will need to establish their safety and efficacy through further trials.
The planned IPO valuation also places attention on the company’s ability to advance its pipeline and reach upcoming clinical milestones. The additional $50 million Sanofi placement represents a separate financing component, but the supplied information does not specify further commercial or development commitments associated with the investment.
Closing Insights
Windward Bio Group’s proposed $175 million IPO, alongside a $50 million private placement to Sanofi, represents a significant planned financing for the recently founded biotechnology company. Its lead candidate, WIN378, is progressing through clinical studies for asthma and COPD, while WIN027 expands its pipeline into additional respiratory and dermatological indications.
The proposed Nasdaq listing will give public-market investors exposure to the company’s antibody development strategy, with the expected 2027 clinical milestones likely to be important points in assessing its progress.
